FY13 Priorities. Avant-Garde (DP1) A- START (R03/$100K) IAS /NIDA Fellowship ($75K) Advancing exceptional HIV /AIDS Research (R01/RFA) Technology-Base Adherence Research (PA) NIDA Drug Abuse and HIV Cohorts (PAR/U01) Provide supplements for NIAID’s ACTG
Jeremy Luban, M.D.
University of Massachusetts, Medical School, Worcester
David Smith, M.D.
University of California, San Diego School of Medicine
Samuel Friedman, Ph.D.
National Development and Research Institutes, New York City
Molecular epidemiology for HIV prevention for drug users and other risk groups
Preventing HIV transmission by recently-infected drug users
Human genes that influence HIV-1 replication, pathogenesis, and immunity in intravenous drug users